Post-earnings recap
Reported
Mon, Nov 5, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that PTC Therapeutics is struggling with its financial performance, particularly reflected in the disappointing EPS. The stock reacted negatively, dropping 4.49% as investors digested the lack of revenue information and forward guidance. The absence of specific financial targets may raise concerns about the company's near-term outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.06 | N/A | -187.06% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced in the quarter. They emphasized their commitment to advancing their pipeline despite the lack of financial guidance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on ongoing clinical trials and product development.